Biogen (BIIB) stock-based compensation was $291M in FY2025 (-0% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$291M
-0%
2024
$291M
+10%
2023
$264M
+200%
2022
-$264M
-7%
2021
-$247M
-21%
2020
-$204M
-7%
2019
-$191M
-13%
2018
-$169M
-232%
2017
$128M
+193%
2016
-$138M
-175%
2015
$183M
+11%
2014
$165M
+13%
2013
$146M
+18%
2012
$124M
+6%
2011
$117M
-31%
2010
$170M
+1%
2009
$167M
+9%
2008
$154M
+20%
2007
$128M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q1 2026
$84M
Q4 2025
$60M
Q3 2025
$75M
Q2 2025
$75M
Q1 2025
$81M
Q4 2024
$366M
Q3 2024
-$75M
Q2 2024
-$73M
Q1 2024
$73M
Q4 2023
$482M
Q3 2023
-$65M
Q2 2023
-$74M
Source: BIIB on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.